Bausch + Lomb Corporation (BLCO) Acquires XIIDRA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Bausch & Lomb Corp. (BLCO) PT Raised to $23 at BofA Securities on new acquisition
July 3, 2023 6:53 AM EDTBofA Securities analyst Craig Bijou raised the price target on Bausch & Lomb Corp. (NYSE: BLCO) to $23.00 (from $19.00) while maintaining a Buy rating.
The analyst is positive on the acquisition of Novartis dry eye disease (DED) drug.
"We see the deal as a meaningful... More
Bausch + Lomb Corporation (BLCO) shares surge on $2.5bn deal to acquire XIIDRA
June 30, 2023 11:19 AM EDTBausch + Lomb Corporation (NYSE: BLCO) shares surged Friday after the company announced a deal to acquire XIIDRA from Novartis for up to $2.5 billion.
BLCO shares are currently up more than 5% at $20.20 after initially hitting a high of $21.95 per share.
The company, through an affiliate, will acquire XIIDRA, libvatrep, and AcuStream in a deal worth up to $2.5 billion, including an upfront payment of $1.75 billion in cash with potential milestone obligations up... More
